Chimeric G proteins allow a high-throughput signaling assay of Gi-coupled receptors.

G-protein-coupled receptors are a major target for potential therapeutics; yet, a large number of these receptors couple to the Gi pathway, generating signals that are difficult to detect. We have combined chimeric G proteins, automated sample handling, and simultaneous 96-well fluorometric imaging to develop a high-throughput assay system for Gi signaling. The chimeric G proteins alter receptor coupling so that signaling can occur through Gq and result in mobilization of intracellular calcium stores. An automated signaling assay device, the fluorometric imaging plate reader (FLIPR), can simultaneously measure this response in real time in 96-well microplates, allowing two people to process more than 10,000 points per day. We used the chimeric G protein/FLIPR system to characterize signaling by the Gi-coupled human opioid receptors. We show that the mu, delta, and kappa opioid receptors and the related nociceptin receptor, ORL1, each couple to Galphaqi5, Galphaqo5, and Galpha16 (Galphaqi5 and Galphaqo5 refer to Galphaq proteins containing the five carboxyl-terminal amino acids from Galphai and Galphao, respectively) and that different receptor/G protein combinations show different levels of maximal activation. We tested 31 opioid ligands for agonist activity at the opioid receptors (124 ligand-receptor combinations); all 31 activated at least one receptor type, and several activated multiple receptors with differing potencies. This high-throughput assay could be useful for dissecting the complex ligand-receptor relationships that are common in nature.

[1]  I. Nishimoto,et al.  A novel system that reports the G‐proteins linked to a given receptor: a study of type 3 somatostatin receptor , 1997, FEBS letters.

[2]  M. Grossmann,et al.  G Protein-coupled Receptors , 1998, The Journal of Biological Chemistry.

[3]  B. Conklin,et al.  Substitution of three amino acids switches receptor specificity of Gqα to that of Giα , 1993, Nature.

[4]  M. Brann,et al.  Pharmacology of muscarinic acetylcholine receptor subtypes (m1-m5): high throughput assays in mammalian cells. , 1996, European journal of pharmacology.

[5]  B. Conklin,et al.  Interactions of Muscarinic Receptors with the Heterotrimeric G Proteins Gq and G12: Transduction of Proliferative Signals , 1997, Journal of neurochemistry.

[6]  T. Petcher,et al.  Bremazocine: a potent, long-acting opiate kappa-agonist. , 1980, Life sciences.

[7]  T. Murphy,et al.  Induction of NFAT-mediated Transcription by G-coupled Receptors in Lymphoid and Non-lymphoid Cells (*) , 1996, The Journal of Biological Chemistry.

[8]  Y. H. Wong.  Gi assays in transfected cells. , 1994, Methods in enzymology.

[9]  L. Weinstein,et al.  Receptor-effector coupling by G proteins: implications for normal and abnormal signal transduction. , 1992, Endocrine reviews.

[10]  B. Conklin,et al.  G alpha 13 stimulates Na-H exchange. , 1994, The Journal of biological chemistry.

[11]  J. Bockaert,et al.  Coupling of metabotropic glutamate receptors 2 and 4 to G alpha 15, G alpha 16, and chimeric G alpha q/i proteins: characterization of new antagonists. , 1996, Molecular pharmacology.

[12]  J. W. Parce,et al.  The cytosensor microphysiometer: biological applications of silicon technology. , 1992, Science.

[13]  L. Goodman,et al.  The Pharmacological Basis of Therapeutics , 1941 .

[14]  W. Stigelman,et al.  Goodman and Gilman's the Pharmacological Basis of Therapeutics , 1986 .

[15]  C. Strader,et al.  Structure and function of G protein-coupled receptors. , 1994, Annual review of biochemistry.

[16]  I. Charo,et al.  Differential Regulation of G-protein-mediated Signaling by Chemokine Receptors* , 1996, The Journal of Biological Chemistry.

[17]  S. Carr,et al.  Orexins and Orexin Receptors: A Family of Hypothalamic Neuropeptides and G Protein-Coupled Receptors that Regulate Feeding Behavior , 1998, Cell.

[18]  R. Harkins,et al.  Heregulin Activation of Extracellular Acidification in Mammary Carcinoma Cells Is Associated with Expression of HER2 and HER3 (*) , 1995, The Journal of Biological Chemistry.

[19]  M. Simon,et al.  Gα15 and Gα16 Couple a Wide Variety of Receptors to Phospholipase C (*) , 1995, The Journal of Biological Chemistry.

[20]  M. Brann,et al.  Pharmacology of muscarinic receptor subtypes constitutively activated by G proteins. , 1997, Molecular pharmacology.

[21]  H. Akil,et al.  The cloned μ, δ and κ receptors and their endogenous ligands: Evidence for two opioid peptide recognition cores , 1995, Brain Research.

[22]  M. Yanagisawa.  The endothelin system. A new target for therapeutic intervention. , 1994, Circulation.

[23]  D. I. Våge,et al.  The melanocortin receptors: agonists, antagonists, and the hormonal control of pigmentation. , 1996, Recent progress in hormone research.

[24]  S. Rees,et al.  A bioluminescent assay for agonist activity at potentially any G-protein-coupled receptor. , 1997, Analytical biochemistry.

[25]  J. Wess,et al.  Molecular Mechanisms Involved in Muscarinic Acetylcholine Receptor-mediated G Protein Activation Studied by Insertion Mutagenesis (*) , 1996, The Journal of Biological Chemistry.

[26]  Eleanor Lawrence,et al.  The encyclopedia of molecular biology , 1995 .

[27]  G Vassart,et al.  ORL1, a novel member of the opioid receptor family , 1994, FEBS letters.

[28]  B. Conklin,et al.  Carboxyl-terminal mutations of Gq alpha and Gs alpha that alter the fidelity of receptor activation. , 1996, Molecular pharmacology.

[29]  Y. Wong,et al.  Differential Coupling of μ‐, δ‐, and κ‐Opioid Receptors to Gα16‐Mediated Stimulation of Phospholipase C , 1998 .

[30]  G. Uhl,et al.  Human mu opiate receptor. cDNA and genomic clones, pharmacologic characterization and chromosomal assignment. , 1994, FEBS letters.